Exploring microbiome dynamics in esophageal cancer

NewsGuard 100/100 Score

Esophageal cancer (EC) has two primary subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). These subtypes differ notably in geographical distribution, risk factors, and clinical characteristics. Despite considerable efforts, EC remains challenging to diagnose and treat due to its frequently late presentation and resistance to conventional therapies.

A comprehensive review (DOI: 10.20892/j.issn.2095-3941.2023.0177), conducted by researchers at Zhengzhou University, Henan Cancer Hospital, and the Marshall Medical Research Center, marks a significant advancement in oncology. Published in the October 2023 issue of Cancer Biology & Medicine, the review highlights important findings regarding microbiome changes in EC and their implications for disease pathogenesis and prognosis. It identifies critical shifts in the microbiome associated with EC and explores how these changes might affect patient outcomes.

The researchers found that specific bacterial changes are linked to different stages of EC. For example, lactic acid-producing bacteria were more common in EAC, suggesting these microbes might support tumor survival by converting glucose into lactate, providing energy for malignant cells. They also noted reduced microbial diversity in ESCC compared to non-tumor tissues. This decrease in diversity was associated with increased levels of Fusobacterium and decreased levels of Streptococcus, indicating that specific microbial profiles may play a role in cancer progression. The study further explored how microbial dysbiosis might affect treatment outcomes. Distinct microbial compositions were associated with varied responses to radiotherapy and chemotherapy, emphasizing the potential of the esophageal microbiome to influence treatment efficacy.

Understanding the role of the esophageal microbiome in the development and progression of EC could lead to earlier detection and more personalized treatment approaches. Our findings suggest that microbial dysbiosis may not only contribute to the pathogenesis of EC but also affect treatment outcomes."

Dr. Hongle Li, one of the study's authors

The research has critical implications for early detection and improved treatment strategies for EC. Identifying microbial markers associated with disease progression could pave the way for targeted therapies that disrupt cancer-promoting bacteria. Moreover, certain microbial profiles could serve as prognostic indicators, aiding in treatment planning and patient monitoring.

Source:
Journal reference:

Li, Y., et al. (2023). Microbiome changes in esophageal cancer: implications for pathogenesis and prognosis. Cancer Biology & Medicine. doi.org/10.20892/j.issn.2095-3941.2023.0177.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Surprising link between a diverse oral microbiome and better cognitive function in aging